You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 17, 2025

Details for Patent: 10,022,344


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,022,344
Title:Liquid dosage forms of sodium naproxen
Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.
Inventor(s): Chidambaram; Nachiappan (Sandy, UT), Fatmi; Aqeel A. (High Point, NC)
Assignee: Patheon Softgels, Inc. (High Point, NC)
Application Number:15/817,471
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,022,344
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,022,344: A Detailed Analysis

Introduction

Patent 10,022,344, like any other patent, is a complex document that outlines the invention, its claims, and the scope of protection it offers. To analyze this patent, we need to delve into its various components, including the background, summary, detailed description, and most importantly, the claims.

Background and Summary

Before diving into the specifics of the patent claims, it is crucial to understand the context in which the invention was developed. The background section typically provides an overview of the existing technology and the problems it addresses. The summary section gives a brief description of the invention and its key features.

Detailed Description

The detailed description section is where the inventor explains the invention in detail, often including diagrams, flowcharts, and other visual aids. This section helps in understanding how the invention works and its various components.

Claims

The claims section is the most critical part of a patent as it defines the scope of protection. Here, we will break down the different types of claims and how they impact the patent landscape.

Independent and Dependent Claims

  • Independent Claims: These claims stand alone and define the invention without reference to other claims. They are crucial because they set the broadest scope of protection for the invention[3].
  • Dependent Claims: These claims refer back to an independent claim and further limit the scope of the invention. They often add specific details or features to the independent claims.

Claim Construction

Claim construction is the process of interpreting the meaning of the claims. This is often a point of contention in patent litigation. The Federal Circuit has established guidelines for claim construction, emphasizing the importance of understanding the ordinary and customary meaning of the claim terms as understood by one of ordinary skill in the art[5].

Patent Eligibility Under 35 U.S.C. § 101

Patent eligibility is a critical aspect of any patent, including 10,022,344. The Supreme Court and the Federal Circuit have established a two-stage framework for determining patent eligibility under 35 U.S.C. § 101.

Stage 1: Determining if the Claim Falls Within a Judicial Exception

Claims must not be directed to laws of nature, natural phenomena, or abstract ideas. If a claim does fall within one of these exceptions, it proceeds to the second stage[5].

Stage 2: Determining if the Claim Adds Significant Limitations

If a claim falls within a judicial exception, it must be determined whether the claim adds significant limitations that transform the abstract idea into a practical application. This involves assessing whether the additional elements in the claim impose meaningful limits on the exception[1].

AI-Assisted Inventions and Patent Eligibility

The 2024 USPTO guidance update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. The focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies. This means that as long as there is significant human contribution, AI-assisted inventions can be patent-eligible[1].

Real-World Applications and Practical Utility

To bolster the argument for patent eligibility, it is essential to highlight the real-world applications of the claimed method or system. Demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field is crucial. For example, if a claim specifies the use of a mathematical model in a real-time speech recognition system to enhance accuracy, it adds a level of practical utility that can make the claim patent-eligible[1].

Obviousness-Type Double Patenting (ODP)

In addition to patent eligibility, the patent landscape also involves considerations of obviousness-type double patenting (ODP). This issue arises when multiple patents, often continuations or continuations-in-part, claim the same invention or obvious variations thereof. The Federal Circuit has ruled that ODP must be evaluated based on the date of expiration of a patent that includes any duly granted Patent Term Adjustment (PTA)[4].

False Patent Marking and Unfair Competition

While not directly related to the claims of a specific patent, false patent marking can impact the broader patent landscape. Recent decisions, such as Crocs, Inc. v. Effervescent, Inc., have revived private actors' rights to bring claims under the Lanham Act for false advertising related to patent marking. This emphasizes the importance of accurate patent marking to avoid unfair competition claims[2].

Measuring Patent Scope

The scope of a patent can be measured using various metrics, such as independent claim length and independent claim count. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes. Narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Key Takeaways

  • Patent Claims: The claims section is crucial as it defines the scope of protection. Independent claims set the broadest scope, while dependent claims further limit it.
  • Patent Eligibility: Claims must not be directed to judicial exceptions and must add significant limitations to transform abstract ideas into practical applications.
  • AI-Assisted Inventions: The use of AI in invention development does not impact subject matter eligibility, provided there is significant human contribution.
  • Real-World Applications: Highlighting real-world applications and practical utility is essential for demonstrating patent eligibility.
  • ODP and PTA: Obviousness-type double patenting must be evaluated based on the date of expiration including PTA.
  • False Patent Marking: Accurate patent marking is crucial to avoid unfair competition claims under the Lanham Act.

FAQs

Q: What is the significance of independent claims in a patent? A: Independent claims stand alone and define the invention without reference to other claims, setting the broadest scope of protection for the invention.

Q: How does the use of AI impact patent eligibility? A: The use of AI in invention development does not impact subject matter eligibility, provided there is significant human contribution and the claimed invention itself meets the criteria for patent eligibility[1].

Q: What is the importance of real-world applications in patent claims? A: Highlighting real-world applications and practical utility is essential for demonstrating how the abstract idea is applied in a way that provides concrete benefits, thereby making the claim patent-eligible[1].

Q: What is obviousness-type double patenting (ODP)? A: ODP arises when multiple patents claim the same invention or obvious variations thereof. It must be evaluated based on the date of expiration including any duly granted Patent Term Adjustment (PTA)[4].

Q: How can false patent marking lead to legal issues? A: False patent marking can lead to claims under the Lanham Act for false advertising, which can result in unfair competition lawsuits[2].

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. The Federal Circuit Breathes New Life into False Patent Marking Claims via Section 43a of the Lanham Act - Spencer Fane
  3. Patent Claims and Patent Scope - SSRN
  4. In re Cellect - United States Court of Appeals for the Federal Circuit
  5. Electric Power Group, LLC v. Alstom S.A. - United States Court of Appeals for the Federal Circuit

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,022,344

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bionpharma NAPROXEN SODIUM naproxen sodium CAPSULE;ORAL 021920-001 Feb 17, 2006 OTC Yes Yes 10,022,344 ⤷  Subscribe Y TEMPORARY RELIEF OF MINOR ACHES AND PAINS ⤷  Subscribe
Bionpharma NAPROXEN SODIUM naproxen sodium CAPSULE;ORAL 021920-001 Feb 17, 2006 OTC Yes Yes 10,022,344 ⤷  Subscribe Y TEMPORARY REDUCTION OF FEVER ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.